IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Just_Observing who wrote (1692)	9/9/1999 3:20:00 PM
From: Jeter C. Hall	Read Replies (1) of 1762

tveyes.com CNBC 9/9/99 - 2:26:27 PM ..... stockinging issues. And in the second quarter, a $68 million number for rituxan sales actually had, because they could get a better price on it in the second quarter versus the third quarter, they're an incremental or an additional 5 million. So people are actually looking at the second-quarter number like $63 million, but he goes on to say he feels idec is sharply oversold at this point and this is the reaction to what the ceo said about rituxan sales being overstated at this point. Also, rituxan, in some fashion, goes into the bullish case on genentech. A lot of that company's growth is going to come from two recently, i guess, approved drugs. Herceptin for breast cancer, which was very well-received as well as well as rituxan for non-hodgkin's lymphoma. Genentech, obviously, has a lot of other drugs, but these two are adding to the incremental growth.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next